COVID-19 Or Co-Pays: Which Is More Complex?
Executive Summary
One of many unresolved issues for the next round of COVID-19 response legislation in the US is whether and how to assure that an eventual vaccine is affordable for all Americans. The House wants to make it free to everyone – which is a lot harder than it sounds.
You may also be interested in...
Senate Republicans Pledge To Build Up Stockpiles Of COVID-19 Diagnostics, Supplies, Under HEALS Act
One of eight legislative bills put out by GOP senators under the umbrella of the HEALS Act coronavirus relief package on 27 July would build up stockpiles of diagnostics and medical supplies.
'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill
Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.